Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07QSA
|
|||
Former ID |
DIB010961
|
|||
Drug Name |
CP-83101
|
|||
Synonyms |
AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; CP-83101; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Terminated | [1] | |
Company |
Pfizer Inc
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H24O4
|
|||
Canonical SMILES |
COC(=O)CC(CC(C=CC=C(C1=CC=CC=C1)C2=CC=CC=C2)O)O
|
|||
InChI |
1S/C22H24O4/c1-26-22(25)16-20(24)15-19(23)13-8-14-21(17-9-4-2-5-10-17)18-11-6-3-7-12-18/h2-14,19-20,23-24H,15-16H2,1H3/b13-8+/t19-,20-/m1/s1
|
|||
InChIKey |
NSZBOSJMBQKKKB-ZCBOBATRSA-N
|
|||
CAS Number |
CAS 130746-82-6
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Inhibitor | [2] |
BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
Superpathway of cholesterol biosynthesis | ||||
Mevalonate pathway | ||||
KEGG Pathway | Terpenoid backbone biosynthesis | |||
Metabolic pathways | ||||
Biosynthesis of antibiotics | ||||
AMPK signaling pathway | ||||
Bile secretion | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
TSH Signaling Pathway | ||||
Panther Pathway | Cholesterol biosynthesis | |||
Pathwhiz Pathway | Steroid Biosynthesis | |||
WikiPathways | Statin Pathway | |||
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
Activation of Gene Expression by SREBP (SREBF) | ||||
SREBF and miR33 in cholesterol and lipid homeostasis | ||||
Integrated Breast Cancer Pathway | ||||
SREBP signalling | ||||
Cholesterol Biosynthesis |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000245) | |||
REF 2 | Efficacy, tissue distribution and biliary excretion of methyl (3R*,5S*)-(E)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoate (CP-83101), a hepatoselective inhibitor of HMG-CoA reductase activity in the rat. Biochem Pharmacol. 1990 Sep 15;40(6):1281-93. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.